CytoMed Therapeutics announced entering into a Memorandum of Understanding with China-based Hangzhou CNK Therapeutics. Under the terms of the agreement, CytoMed will be able to utilize CNK’s PiggyBac technology to permanently graft the Chimeric Antigen Receptor gene directly into its patented gamma delta T-cells through a non-viral gene editing method. The MOU will have an initial duration of one-year, with an option to renew and remains subject to definitive agreements and other customary closing conditions. In addition, there remains a possibility for CytoMed and CNK to engage in a joint venture to conduct clinical trials within China.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GDTC:
- Cytomed Therapeutics granted Chinese patent for CAR-gamma delta T Cell
- Abbott upgraded, Carvana downgraded: Wall Street’s top analyst calls
- Benchmark starts Cytomed with Speculative Buy on ‘promising’ pre-clinical data
- Cytomed Therapeutics initiated with a Speculative Buy at Benchmark
- Cytomed Therapeutics’ A*STAR announce patent for CAR-gamma delta T cell tech